GenMark Diagnostics Guides to Q2 Revenues of $3.2M to $3.6M, Raises Full-year 2012 Revenue Guidance | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics today provided second-quarter revenue guidance and raised its full-year 2012 revenue guidance.

For the quarter ending June 30, the Carlsbad, Calif.-based molecular testing firm said that revenues are anticipated to fall between $3.2 million and $3.6 million. Full-year 2012 revenues are now expected to top $15 million. GenMark said in its fourth-quarter and full-year 2011 earnings announcement that 2012 revenues would exceed $10 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.